Refractory Major Depressive Disorder Clinical Trial
A Phase 3b Extension Study of Adjunctive ALKS 5461 in the Treatment of Refractory Major Depressive Disorder
This study will assess the long-term safety and tolerability of ALKS 5461 as an adjunctive treatment for refractory MDD.
|Status||Enrolling by invitation|
|Start date||August 9, 2018|
|Completion date||July 2021|